Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
156 hedge funds and large institutions have $1.02B invested in Momenta Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 66 increasing their positions, 44 reducing their positions, and 26 closing their positions.
71% more call options, than puts
Call options by funds: $5.78M | Put options by funds: $3.37M
50% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 44
4% less funds holding
Funds holding: 162 → 156 (-6)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
27% less capital invested
Capital invested by funds: $1.4B → $1.02B (-$384M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$25.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.5M |
| 4 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$10.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$54.4M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$12.3M |
| 3 |
JP Morgan Chase
New York
|
-$5.86M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.34M |
| 5 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
-$4.27M |
MNTA Hedge Fund Activity: Q3 2015 in Review
156 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2015, worth a combined $1.02B — down 27% from $1.4B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MNTA and 21 opened new positions — a net loss of 5 holders — while 44 trimmed existing stakes and 66 added.
The largest buyer was Visium Asset Management, adding an estimated $25.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $54.4M.
- 156 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2015, down from 162 in Q2 2015.
- Funds reported $1.02B of Momenta Pharmaceuticals, Inc. stock for Q3 2015, down 27% quarter-over-quarter.
- 21 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2015 and 26 closed out, a net change of -5 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2015 was Visium Asset Management, an estimated $25.7M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q3 2015 was T. Rowe Price Associates, an estimated $54.4M sold.
Based on aggregated 13F filings for Q3 2015.